Close menu

November 10th, 2023 | 09:15 CET

Healthcare and Logistics in Focus with Amazon, First Hydrogen, Bayer - Where growth is created

  • Hydrogen
  • greenhydrogen
  • Logistics
  • Healthcare
  • Technology
Photo credits:

Telemedicine is a blessing for anyone lying in bed with a fever and in need of a doctor or medication. Now, 167 million Americans can benefit from it. Amazon rolled out the telemedicine service to all Prime members in the States this week. To ensure that deliveries arrive on time and with as few emissions as possible, First Hydrogen has developed a van that has already successfully passed its test phase in the UK. A range of 630 km can be covered on one hydrogen charge. But that is not all; the Company is planning much more in the field of hydrogen. After sobering figures, Bayer AG is focusing on drastic measures instead of innovations, but these will benefit those who truly do their job. We take a glance at the details.

time to read: 5 minutes | Author: Juliane Zielonka
ISIN: AMAZON.COM INC. DL-_01 | US0231351067 , First Hydrogen Corp. | CA32057N1042 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:

    Sebastian-Justus Schmidt, CEO and Founder, Enapter AG
    "[...] Why should a modular electrolyzer cost more than a motorcycle? [...]" Sebastian-Justus Schmidt, CEO and Founder, Enapter AG

    Full interview


    Amazon launches telemedicine service for 167 million Prime members in the US

    In Germany, employees who wake up feeling unwell have to drag themselves to their GP for a possible sick note. What worked well over the phone during the coronavirus pandemic to relieve the pressure on doctors' surgeries was repealed by German lawmakers on April 1, 2023. While the bureaucracy monster is wreaking havoc in Germany, Amazon has now established a pragmatic, time-saving solution.

    As of this week, Prime members in the US have been able to use Amazon's in-house telemedicine service. This means that around 167 million Prime subscribers in the US can use the 24-hour service at any time.

    For investors, whose main job is to think into the future to discover the greatest possible returns, this news has enormous potential. With 167 million potential diagnoses, Amazon can develop data pools that other analytics companies or the National Health Authority CDC in the US can only dream of. With in-house technical expertise, Amazon data engineers can use predictive analytics to calculate heat maps of infections, waves of disease, etc. With appropriate modeling software, other sources of spread can also be predicted and contained in good time.

    Employers benefit from the time saved that employees would otherwise need to drive across town to the doctor, including a stay in the waiting room, to finally obtain a sick note. Unlike in European countries, health benefit contracts in the US are often linked to the employer: more available working time, more potential productivity.

    According to Statista, turnover in the US digital health market is expected to reach USD 44.45 billion. Revenue is estimated to grow at a CAGR of 8.54% from 2023 to 2028, resulting in a projected market volume of USD 66.96 billion by 2028. The average return per user (ARPU) is expected to amount to USD 137,700.

    If Amazon succeeds in cracking this lucrative vertical, this means further growth opportunities for the share. The share is currently trading at EUR 132.50.

    First Hydrogen - Hydrogen drive for transportation companies

    Amazon is represented in eight European countries. The combined number of sellers in these countries accounts for 24% of Amazon sellers worldwide. The German and UK markets are not only the oldest European Amazon marketplaces but also the most lucrative in terms of net sales. Amazon Germany topped the ranking of the most profitable marketplaces in Europe in 2021 with EUR 31.6 billion in net sales and was followed by Amazon UK in 2nd place with EUR 27.9 billion. Overall, net sales increased by 13% to USD 134.1 billion in Q3/2023, compared to USD 119 billion in Q3/2022. Whether Amazon parcels, medicines or groceries, all these goods are transported to their destination in vans every day. Amazon ships approximately 1.6 million packages per day. That equates to more than 66,000 orders per hour and 18.5 orders per second.

    It is precisely here where the Company First Hydrogen comes into play. Based in Vancouver and London, the First Hydrogen focuses on zero-emission transportation and the production and distribution of green hydrogen. In collaboration with AVL Powertrain and Ballard Power Systems Inc., First Hydrogen has designed and built light commercial vehicles with hydrogen fuel cells ("FCEV"). These vehicles have a range of more than 630 km on a single charge and are currently undergoing practical trials in the UK.

    Visitors from the industry could see for themselves at the Horiba Mira Technology Park at the end of October that the FCEV vehicle developed by First Hydrogen is a commercially viable solution.

    In addition, First Hydrogen plans to build a 35 MW facility for green hydrogen production and a factory for vehicle assembly in Shawinigan, Quebec. For investors who want to be part of an exciting candidate in the growing logistics market from the beginning, First Hydrogen is worth analyzing. After all, hydrogen propulsion has already arrived in the US, at least on the rails.

    Bayer quarterly figures sobering, next measure: Streamlining management

    Bayer CEO Bill Anderson spoke candidly when presenting the quarterly figures for Q3/2023: "We are not satisfied with our performance this year." The American, who took over from Werner Baumann in the spring, still has his hands full. Firstly, Anderson plans to streamline Bayer AG's bloated management structure. He wants to shift most of the decision-making powers from the managers to the employees who actually carry out the tasks. Twelve layers of management between him and the Company's customers are "simply too much".

    A possible split of the three Group divisions: Pharmaceuticals, Crop Science and Consumer Health is still conceivable. Whether it will be the problem child Crop Science together with Monsanto or Consumer Health, Anderson has not yet said anything about this. Bayer AG's total sales amounted to USD 11.25 billion this time but fell short of analyst estimates. Crop Science sales remained stable, while pharmaceutical orders in China declined. However, new products such as Nubeqa™ (for prostate cancer) and Kerendia™ (for the treatment of chronic kidney disease in adults with type 2 diabetes) recorded growth. Investors are somewhat critical of the fact that Anderson is currently turning over every stone in the Group. The share has lost 20% of its value in the last 12 months and currently stands at EUR 41.98.

    Amazon has introduced a telemedicine service for 167 million Prime members in the US, creating a potential data source for health data and its analysis. This offers enormous potential for predictive analytics and is a significant step towards conquering the healthcare market. First Hydrogen focuses on zero-emission transportation with hydrogen fuel cells. According to Fortune Business Insights, the global electric vehicle market was estimated at USD 384.65 billion in 2022 and is expected to grow from USD 500.48 billion in 2023 to USD 1,579.10 billion by 2030. The Company is also planning a green hydrogen production plant, which will further solidify the business. Bayer posted disappointing quarterly figures and is planning a management streamlining. A possible split-up of the business units is under discussion. Investors are taking a critical view of the business, with the result that the shares have lost 20% in the last 12 months. There are signs of growth at Amazon in the medical division, followed by the hydrogen-powered transporter from First Hydrogen. CEO Anderson, on the other hand, still has some tidying up to do at Bayer and some pruning here and there before new growth can emerge.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author

    Related comments:

    Commented by André Will-Laudien on April 23rd, 2024 | 07:45 CEST

    Attention: DAX dividends! Car stocks pay out: Mercedes-Benz, MS Industrie, VW and BMW

    • Technology
    • hightech
    • Automotive
    • Electromobility

    The DAX 40 index has gone into reverse gear in recent weeks. In addition to the high-tech and artificial intelligence sectors, the multi-month bull market also included defense stocks in the interim phase. There is no real reason to celebrate among automotive stocks, as an expected decline in GDP also means reduced household budgets. This translates to fewer new vehicle sales, with many electric vehicles produced in bulk occupying important showroom space from dealers for months. The pain is increasing, and those looking to sell vehicles find themselves in ruinous discount battles with cheap Chinese imports. However, there appears to be a glimmer of hope on the horizon: interest rate cuts! They are expected in the second half of the year. We analyze the current situation.


    Commented by Juliane Zielonka on April 22nd, 2024 | 07:00 CEST

    Cardiol Therapeutics, Bayer AG, Fresenius - Who will be the trendsetter in tomorrow's healthcare market?

    • Biotechnology
    • Pharma
    • Healthcare

    The healthcare sector is a lucrative segment for risk-conscious investors. The global healthcare services market size is expected to achieve a compound annual growth rate (CAGR) of 8.96% by 2028. Understanding local healthcare needs is the basis for the growth of companies such as Cardiol Therapeutics, Bayer and Fresenius. Cardiol Therapeutics is a promising life sciences company researching several heart diseases with a focus on heart health and developing suitable medication. A disease such as heart failure (HF), for example, affects 26 million people worldwide and offers high scaling potential for the Canadian researchers and developers at Cardiol. Bayer also recognizes the market potential and would like to supply this target group with a gene therapy via Fast Track. Fresenius is familiar with market conditions due to expiring patent protection and is launching a lucrative biosimilar in the US. Which of these three companies will set the trend in the healthcare market of the future?


    Commented by Juliane Zielonka on April 18th, 2024 | 07:00 CEST

    Volkswagen, Altech Advanced Materials, BYD - who can benefit from China's rise

    • Innovations
    • Technology
    • Electromobility
    • Batteries

    Chinese companies such as BYD benefit from state subsidies and domestic access to raw materials. BYD's subsidies have risen from EUR 220 million in just three years to EUR 2.1 billion. These sums are helping BYD dominate the Chinese electric vehicle market and increasingly penetrate the European market. Volkswagen cannot escape the pull of China either. As part of its "In China, for China" strategy, Volkswagen is expanding its cooperation network with Chinese partners. The aim is to reduce costs significantly in the development of EV technology. For companies like Altech Advanced Materials, close cooperation with Chinese market leaders such as BYD and Volkswagen offers the opportunity to commercialize innovative battery technologies that meet the needs of the changing market. One of these innovations, made in Germany by Altech Advanced Materials, increases the longevity of EV batteries by 30%. Here are the details.